Clinical and Experimental Hepatology
eISSN: 2449-8238
ISSN: 2392-1099
Clinical and Experimental Hepatology
Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications
3/2025
vol. 11
 
Share:
Send email
Share:
abstract:
Original paper

Impact of the removal of treatment barriers on the microelimination of chronic hepatitis C in Slovak prisons: experience from real-life settings

Ivana Hockicková
1
,
Ján Hockicko
1
,
Peter Jarčuška
2
,
Sylvia Dražilová
2
,
František Lami
1
,
Patrícia D. Lenártová
1
,
Pavol Mrážik
3
,
Adrián Gábor
4
,
Pavol Kristian
1

  1. Department of Infectology and Travel Medicine, Faculty of Medicine, P.J. Šafárik University, and L. Pasteur University Hospital, Košice, Slovakia
  2. 2nd Department of Internal Medicine, Faculty of Medicine, P.J. Šafárik University, and L. Pasteur University Hospital, Košice, Slovakia
  3. Correctional Facility, Košice-Šaca, Slovakia
  4. Remand Prison and Correctional Facility, Košice, Slovakia
Clin Exp HEPATOL 2025; 11, 3: 271–278
DOI: https://doi.org/10.5114/ceh.2025.154078
Online publish date: 2025/09/16
View full text Get citation
 
PlumX metrics:
Aim of the study:
To evaluate the real-life experience of microelimination of chronic hepatitis C in Slovak prisons. We assessed the impact of removing treatment restrictions on the number of treated patients and the time from diagnosis to treatment initiation.

Material and methods:
A retrospective analysis was conducted on 205 incarcerated patients diagnosed with chronic hepatitis C between 2018 and 2024 in five prisons in Eastern Slovakia. We compared patient data before and after the removal of treatment indication restrictions.

Results:
Of the total of 205 patients, 94.1% (n = 193) were men. A history of intravenous drug use was reported by 93.7% of patients. Liver fibrosis stage F0-F1 had been confirmed in 74.9% and liver cirrhosis in 5.8% of patients. Additionally, liver cirrhosis was significantly associated with older age (p < 0.0005). The most common HCV genotypes were 3a (30.7%), 1a (23.4%) and 1b (21.5%). Following the complete removal of treatment restrictions in March 2024, the number of treated patients in 2024 increased more than threefold compared to 2023 and fourfold compared to the previous annual average. The time from diagnosis to treatment initiation was significantly reduced from 325 days to 91 days (p < 0.0005). Among treated patients, 98.2% achieved an end-of-treatment response (ETR), and 98.4% achieved a sustained virological response (SVR).

Conclusions:
The removal of treatment restrictions significantly improved access to therapy for incarcerated patients with HCV. Prisons provide a controlled setting for microelimination efforts, and expanding treatment in this population could contribute to broader national HCV elimination goals.

keywords:

treatment, chronic hepatitis C, prisons, real-life experience, treatment barriers
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2025 Termedia Sp. z o.o.
Developed by Bentus.